ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across the globe and maintains offices, R&D centers, and production bases in 12 different cities within the United States, Switzerland, England, Germany, and China. ACROBiosystems Group has established numerous long-term and stable partnerships with the world’s top pharmaceutical enterprises, including Pfizer, Novartis, and Johnson & Johnson, and numerous well-known academic institutes. The company comprises of several subsidiaries such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics.

ACROBiosystems’ brands include FLAG, Star Staining, ViruStop, Aneuro, ComboX, GENPower, and many others. Its main products and services are recombinant proteins, kits, antibodies, scientific services, and other related products. ACROBiosystems employs a strict quality control system for its products that are used in biopharmaceutical research and development, production, and clinical application. This includes targeted discovery and validation, candidate drug screening/optimization, CMC development and pilot production, preclinical research, clinical trials, commercial production, and clinical application of companion diagnostics.

Through the continuous development of new technologies and products, ACROBiosystems Group creates value for the global pharmaceutical industry and actively empowers our partners. The company is dedicated to accelerating the drug development process, including targeted therapies, immunotherapeutic drugs, and its clinical applications, and contributes to global health.

Products
Recombinant proteins
GMP Grade CytokinesNew
Fc receptor proteins
FcRn Proteins
IgG Fc Proteins (Isotype Control)
CGT development solutions New
Targets of CAR-T cell therapy
New Generation Tools for CAR DetectionStar Staining
FDA DMF filed proteins
Multi-pass TpsHot
Immune checkpoint proteins
ADC targets
BsAb targets
TME pathway targets
CytokinesHot
Enzymes
Llama IgG Fc fusion protein
Biosimilar drug targets
Biomarkers & CD antigens
All recombinant proteins

Antibodies
Anti-idiotypic antibody
Anti-FMC63 mAb
Neutralizing antibodies
IgG Isotype Controls: Anti-DNP Antibodies
Support on research about infectious diseases Hot
Core reagents for infectious disease researchNew
SARS-CoV-2 related products
Reagents for vaccine development
SARS-CoV-2 mutant products
SARS-CoV-2 related kits
Reagents for diagnostic development
Kits/Beads
Pre-coupling magnetic beads
Inhinitor screening kits
ELISA Assay Kits for Quantitative analysis of therapeutic antibodies in serum

Innovation Lab Services
SPR /BLI analytical service
Enzyme-Linked Immunosorbent Assay (ELISA) Service
Meso Scale Discovery (MSD) Service
Anti-Idiotypic Antibody Development Service
Pseudovirus Neutralization Assay Service
MHC Class I Complex Custom Service

Licensing Opportunities
Target 4-1BB monoclonal antibody
PD-1/CD80 bispecific antibody
Antagonizing TSP1/CD36 Polypeptide Blocking the activation of TGF-β1
Anti-PD-L1 / TIGIT bispecific antibody
TIGIT-Fc protein
Novel small molecule drug for cancer cachexia

2010